Genetic Engineering Immune Response Protein Research 
Drug Discovery World
JULY 5, 2023
Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. MG: I am responsible for Agilent’s cancer segment. RA: What is the current state of the cancer research industry? Mark Garner, PhD.,
Drug Discovery World
SEPTEMBER 9, 2022
A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of advanced cancers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Advarra
JANUARY 11, 2024
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.
Cloudbyz
MARCH 5, 2024
Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.
The Pharma Data
JUNE 1, 2022
Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. The research was published online recently in Proceedings of the National Academy of Sciences.
pharmaphorum
MARCH 10, 2021
The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 The latest research is published in the New England Journal of Medicine. 1 mutations, as well as variants from the UK and South Africa.
XTalks
NOVEMBER 23, 2020
Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.
Expert insights. Personalized for you.
98 
Let's personalize your content